Earli Inc. Secures $20 Million in Series A Funding to Pioneer Synthetic Biopsy Technology for Benign Cancer Experience

Earli Inc., a pioneering force in the fight against cancer, has successfully raised an impressive $20 million in a recent funding round, further advancing its mission to transform cancer into a benign experience. Based in South San Francisco, the heart of the West Coast’s biotech innovation, Earli is at the forefront of cancer diagnostics and treatment through its groundbreaking technology known as the Synthetic Biopsy. Unlike traditional methods that depend on biomarkers which can be unreliable or absent, Earli’s novel approach leverages gene therapy to compel cancer cells to produce a synthetic, non-human biomarker. This innovative method allows for precise localization of cancer within the body using advanced PET scanning techniques, thereby enhancing both diagnosis and treatment planning. The recent funding round saw participation from industry leaders such as Andreessen Horowitz's Bio Fund, Khosla Ventures, Perceptive Advisors, and several other esteemed investors, including Marc Benioff and Menlo Ventures. This significant infusion of capital will enable Earli to accelerate the development of its Synthetic Biopsy technology, expand its research capabilities, and ultimately lead to improved patient outcomes. With a dedicated focus on revolutionizing cancer care, Earli Inc. is poised to change the paradigm of cancer diagnosis and treatment, moving us one step closer to a future where cancer is no longer a life-altering disease, but rather a manageable condition.